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Introduction: 
Antibody drugs represent a viable treatment option for cancer and autoimmune conditions 
[43,65,74,95,109,146]. However, the future of antibody therapeutics in the treatment of central nervous 
system (CNS) disorders remains unclear. This uncertainty is underscored by a growing list of antibody 
drug trials that failed to meet clinical endpoints in the treatment of Alzheimer’s disease (AD) and 
multiple sclerosis (MS) [43,51,54,86,102,126]. By contrast, many peripheral nervous system (PNS) 
conditions have proved tractable to antibody treatments [43,146]. One major difference between the 
CNS and PNS is that the tissues of the CNS are both physically sequestered and actively protected from 
chemical and biological entities in the blood via the blood-brain barrier (BBB) [20,22]. The primary 
limiting components of the BBB are a layer of endothelial cells (ECs) connected via cross-linked “tight-
junctions” that severely restrict extracellular diffusion of large molecules into the brain parenchyma, 
greatly decreased micropinocytosis, and a loss of transcellular leakage [20,22]. Thus, the failure of 
antibody treatments for CNS diseases may simply stem from the inability of these drugs to reach their 
intended targets [22]. This problem poses a significant challenge for large protein drugs, such as 
antibodies, for which there is no specific mechanism in the BBB for entering the brain [16]. However, if 
approaches can be developed that can deliver antibody drugs across the BBB, many therapeutics that 
failed in previous clinical trials may get a second chance. 
Here, we review antibody therapy research of AD from the perspective of BBB permeability. 
Although presently unsuccessful from a clinical standpoint, previous AD clinical trials with antibodies 
have established the importance of improving antibody penetration into the brain 
[43,51,54,86,102,126]. BBB drug penetration is also a critical facet in the treatment of other CNS 
disorders as well [43]. Development of AD antibody drugs with increased penetration into the brain 
parenchyma will enable clinicians to transfer this success into new classes of antibody therapy for 
Parkinson’s disease, MS, and brain cancer.  
In the case of AD treatment, early antibody drug design initially focused on the drug’s ability to 
selectively target a particular protein [11,51,54,86,90,102,126]. The most common targets were those 
that were thought to modify the levels of toxic oligomers and aggregates of the Aβ peptide in the brain 
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[11,51,54,86,90,102,126]. During the development of these antibody therapeutics, studies had shown 
IgG antibodies delivered to the brain to induce different and more profound effects than those delivered 
intravenously [94,140,144]. However, redesigning antibody drugs in the pipeline for increased BBB 
penetration was a secondary priority [90,102].  
The initial emphasis on prioritizing antibody:target binding over BBB pharmacokinetics stemmed 
from a number of factors. First, some studies supported the premise that the BBB becomes “leaky” or 
more permissive to passage as AD progresses [48,56,78,93,164]. Second, while most studies indicate low 
BBB penetration of IgG in normal humans and mice as well as those with AD (0.1-0.2% brain:blood 
concentrations) [12,16,23,47,51,97], some research suggested that the BBB penetration by anti-Aβ IgG 
might be higher [34,49]. Third, early preclinical studies and Phase I trials also suggested that therapeutic 
IgG could alter AD pathology at relatively low brain levels in the brain via mechanisms of peripheral sink 
[47], central sink [23,129], central sequestration [156], and/or neutralization of Aβ toxicity [52,97,121]. 
In particular, the peripheral sink mechanism was  supported by early studies reporting lower serum 
levels of anti-Aβ IgG in AD patients than healthy controls [55], although subsequent studies found 
contradictory reports of this particular biomarker [83].   
Given the benefit of hindsight, we now know that AD-related BBB disruption does not increase 
penetration of therapeutic IgG significantly. Scientific evidence suggesting an excessively leaky BBB in 
AD patients was predicated on an increased level of peripheral proteins in cerebrospinal fluid (CSF) and 
in immunostained neural tissue [58]. Despite this evidence, an equivalent number of studies found no 
difference in this metric between AD patients and age-matched controls [57,58]. One complication in 
these studies is that most AD patients also experience vascular disease, which is much more highly 
correlated with BBB disruption than AD [57,58]. In addition, lower CSF production and Aβ BBB 
transporter activity are found in AD, both which could also increase peripheral protein concentrations in 
the CSF [20,21,57,72,135]. Lastly, all studies that explicitly tracked BBB penetration of Positron Emission 
Tomography and Magnetic Resonance Imaging sensitive dyes in human subjects [57]  and IgG influx into 
mice [16,19,23] did not find a correlation between drug penetration and AD. In fact, drug penetration 
has been shown to remain low even when the BBB is known to be physically disrupted [35]. In light of 
these findings, it is reasonable to conclude that typical anti-Aβ IgG drugs access the brain parenchyma at 
low levels in AD patients.       
A more urgent interest in antibody BBB penetration emerged after the first generation of 
antibody therapeutics for AD failed to deliver the desired results in Phase III clinical trials 
[51,54,86,97,126]. Aβ oligomers and aggregates in the CNS were not reduced to the degree found in 
animal models, either being lower [126] or remaining unchanged [51,54] after treatment. Most 
importantly, there was a notable lack of significant clinical efficacy compared to placebo for all 
treatments [51,54,86,97,126]. The treatments did shift Aβ and/or tau biomarkers in the desired 
direction [54,126] and select patient subgroups showed a possible benefit [54,86]. However, these 
effects were small and none of these treatments are viable in their current formulation for treatment of 
AD patients. Target selection by anti-Aβ antibodies is likely to remain an important factor. But many new 
efforts have focused on methods or modifications that will increase the concentration of these 
antibodies in the brain [27,128]. If such methods are successful, future anti-Aβ antibody therapeutics 
may prove more effective than those tested up to this point. 
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Recent results of the PRIME study with the chimeric antibody aducanumab support the need to 
increase BBB penetration of antibodies and also provides encouraging results for a viable treatment of 
AD [134]. This Phase I study indicated that aducanumab was capable of both reducing amyloid plaque 
load and slowing cognitive decline in humans. Aducanumab differs from other monoclonal therapeutic 
antibodies in that it is a human antibody that was designed to be highly selective for aggregated forms 
of Aβ [134]. Specifically, the affinity of aducanumab for aggregated Aβ is more than 1000-fold higher 
than that of monomeric Aβ (KD > 10 µM) [134]. In addition to this enhanced target specificity and 
affinity, two other notable outcomes beyond the clinical metrics were also noted after the clinical trial. 
The first outcome is that the BBB penetration was 13 times higher (1.3% brain to plasma) than typical 
therapeutic antibodies (~0.1%) [97,134]. The second outcome is that its mode of action for Aβ reduction 
appears to rely on microglial activation within the brain itself than on facilitating export of Aβ out of the 
brain [134]. 
 The efficacy of advucanumab needs to be confirmed in a larger trial. That said, in comparison 
with previous studies, this trial establishes a positive correlation between BBB penetration and clinical 
efficacy of anti-Aβ antibodies [97,134]. In addition, it also suggests a clinical model where a major 
clinical process, microglial activation, is effected by the antibody within the brain. If microglial activation 
is central to the success of this drug, increasing the concentration of aducanumab in the brain will be a 
key factor in its clinical outcomes. This review serves to explore the means to better achieve this goal. 
Increasing IgG influx 
IgG influx into the brain is limited due to extensive tight junctions and other changes in the 
endothelial layer of the BBB [17]. Influx of endogenous antibodies does not occur by use of transporters 
or adsorptive transcytosis, but by the much slower extracellular pathways [17]. With only extracelluar 
pathways to use, the BBB influx rate of endogenous IgG is comparable to albumin [16,113].   
To increase anti-Aβ IgG delivery to the brain, a number of strategies are being developed to 
increase influx through the BBB (Figure 1). Influx-enhancement strategies roughly fall into one of three 
categories: (1) increasing influx through existing extracellular and transcytotic pathways; (2) a “Trojan 
Horse” approach in which the antibody, as a single engineered antibody or with a second engineered 
carrier molecule, is targeted to a specific BBB transport system and (3) targeted disruption of the BBB. 
The first two specifically increase the antibody influx while the third opens the BBB non-specifically. 
 
Enhanced influx of IgG fragments. One approach that increased antibody influx was the use of F(ab)2 
fragments of anti-Aβ IgG.  These fragments are able to penetrate the BBB at higher rates than their 
parent IgG constructs [115] with comparable therapeutic efficacy in AD animal models [143]. Even 
smaller scFv fragments of anti-Aβ IgG (27 kDa) likewise result in increased BBB influx, Aβ clearance, and 
cognitive improvement in AD mouse models [101]. Smaller yet are anti-Aβ VHH single chain domains, 
i.e.”nanobodies”, derived from llama antibodies (12 kDa) [59]. In addition to their high thermal and 
chemical stability, VHH domains exhibit a comparable antigen affinity to scFv domains despite having 
only three complementarity determining regions [97]. An anti-Aβ VHH fragment was reported to have an 
unprecented brain to blood ratio of 0.6 in AD mouse models [124]. However, the ability of anti-Aβ VHH 
nanoboddies to clear CNS amyloid and improve AD pathology in AD mouse models remains to be seen 
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[104].  Why these fragments cross more quickly is not completely clear, but they likely employ some 
mechanism in addition to the extracellular pathways, possibly adsorptive transcytosis. 
Despite the advantages of antibody fragments, one notable limitation is their high turnover in 
serum [59,101,124]. This rapid loss of peripheral drug concentration prevents their ability to reach 
therapeutic levels in the CNS. One strategy to minimize antibody fragment clearance is to deliver them 
slowly or via multiple injections, although this is highly challenging for the treatment of human patients 
[124]. A second strategy to increase the residency time of these fragments is to link them to an Fc 
domain [59,124]. After 48 hours from infusion in AD transgenic mice, an anti-Aβ VHH-Fc exhibited a 40-
fold higher serum concentration than the isolated VHH fragment [124]. Unfortunately, the brain 
concentration only increased 4-fold, indicating that inclusion of the Fc domain reduced the brain/blood 
ratio 10-fold [124]. A third strategy is to bypass peripheral delivery, as intranasal delivery of anti-Aβ scFv 
slowed amyloid accumulation in AD mice [101]. As single chain proteins, scFv and VHH domains could 
also be released continuously via a gene therapy approach using the adeno-associated virus as a vector 
[101]. While direct central delivery to the brain is not likely to sit well with human patients, 
intramuscular vector delivery and expression may be a viable option. Expression of anti-Aβ scFv enabled 
delivery of this drug to the brain over many months, reduced amyloid burden and reversed cognitive 
impairment in AD mice [101]. While promising, it is unclear whether AD immunotherapy 
implementation via gene therapy will gain traction in clinical applications. 
 
Trojan Horses. The Trojan horse approach is best defined by genetic engineering of bispecific 
antibodies. Bispecific antibodies (bsAbs) consist of at least two distinct structural units – one unit which 
binds a known transporter on the BBB and a second unit which binds the clinical target [27,84,87,104]. 
The target-binding unit is either an intact bivalent IgG [105], presented for monovalent binding by one 
of the two Fab domains (Figure 1) [160], as a smaller scFv domain [28,141], or nanobody VHH domain 
[84].  Likewise, the transporter-binding unit is also designed in a variety of forms, ranging from a second 
IgG antibody domain [27,87], a substitute for one of the two antigen-binding Fab domains (Figure 1) 
[160], an extra Fab domain [105], or an extra VHH domain [59]. Depending on the bsAb design, a single 
bsAb can present multiple target-binding units and/or multiple transporter binding units [84,104]. In 
addition, the number of Fc domains can be increased, or removed altogether, to modulate the effector 
function and bsAb stability [59,84,104]. 
In the ideal case of AD treatment with bsAbs, the transporter-binding unit binds an endogenous 
receptor eventually bringing itself and the rest of the bsAb through the BBB and into the brain (Figure 1) 
[27,59,87,104,110]. The two most common transporters used for this purpose are transferrin and insulin 
[27,59,87,104,110]. Once in the brain, the second clinical functionality will bind its target – such as Aβ, 
beta-secretase, or other AD-related target [105,160]. A substantial number of bsAbs are in development 
for a variety of indications and  a small number have been approved for use by the FDA [84]. By contrast, 
bsAbs designed to enhance BBB influx have yet to leave preclinical stages. One issue here is that the 
transporter-binding unit of most bsAb antibodies for CNS disorders targets the transferrin receptor, a 
receptor found in many tissues. Although bsAbs are designed to avoid inhibition of transferrin binding, 
bsAbs targeting the transferrin-receptor have non-negligible toxicity and safety concerns [39,107]. Such 
safety issues may be avoided by targeting transporters found only in BBB endothelium, such as putative 
receptor Cdc50A by the FC5 VHH nanobody domain [2,59]. The availability of multiple possible bsAb 
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influx routes suggests one will prove successful. Time will tell if bsAbs can benefit AD treatment beyond 
that of standard antibody therapies. 
A second method to produce Trojan Horse antibodies is chemical modification. The ability of 
covalently-linked synthetic groups to enhance influx of antibodies and other proteins through the BBB 
has been known for at least two decades [114]. It is hypothesized that this increased brain penetration 
results from adsorptive endocytosis after binding between the synthetic moieties on the protein with 
the negatively charged membrane surface or lipid rafts (Figure 1) [104,157]. However, the synthetic 
groups might also target a specific transporter that enables BBB transport [114]. Regardless of the 
mechanism, covalent modifications with polyamines and block copolymers have been shown to 
significantly enhance delivery of antibodies to the brain [115,157]. In particular, the BBB penetration of 
anti-Aβ IgG has been shown to be enhanced 50-fold by polyamine modification, with minimal change in 
Aβ binding affinity [115,119].  While clearly beneficial in drug delivery, translational efforts have been 
hindered by an incomplete understanding of its exact chemical nature, safety profile, and mechanism of 
enhanced action [128].  
To overcome these issues, an “in-trans” approach has been developed to deliver large proteins 
into the brain that does not require chemical modification of the protein [128].  In this strategy, the 
protein drug is co-injected with a second “carrier” peptide than binds the drug and also targets a 
receptor on the BBB [128]. A popular carrier peptide for in-trans delivery of both IgG and enzymes is 
K16ApoE [99,128]. K16ApoE consists of 16 lysines, which bind the protein drug, and a domain of ApoE 
which binds the low density lipoprotein receptor (LDLR) found in the BBB (Figure 1) [128]. Although 
K16ApoE succeeds in delivering its cargo into the brain, it is toxic at the levels needed for AD treatment 
[128]. This toxicity will need to be mitigated before this approach can be used in clinical practice. 
 
BBB Disruption. Recent technology advances have enabled ultrasonic pulses that temporarily 
disrupt targeted sections of the BBB via microbubble cavitation [33,76,77,89]. Unlike the specific uptake 
of modified IgG drugs, this intervention opens the BBB non-specificically, allowing passage of drugs and 
endogenous proteins alike [33,76,77,89]. To maximize drug delivery and mitigate unwanted side-effects, 
the timing and location of the pulses must be precisely matched to the administration of the drug 
[33,76]. Increased BBB penetration and enhanced clearance of Aβ by an anti-Aβ antibody has been 
demonstrated in an AD mouse model [76]. Surprisingly, Aβ clearance and cognitive benefits in AD 
transgenic mice are also reported after ultrasonic pulsing when no drug was administered [77,89]. This 
finding suggests endogenous proteins may also facilitate Aβ removal in the event of significant BBB 
disruption [77,89]. While clinical trials using this technology have begun for cancer treatment, its 
effectiveness with AD patients has not yet been shown [33].     
 
The neonatal Fc receptor – an endogenous IgG BBB transporter 
The neonatal Fc receptor (FcRn) has been shown to transport IgG in a saturable mechanism 
across the BBB endothelium [38,45,162]. FcRn has been shown to facilitate rapid efflux of excess IgG 
from the brain after intracerebroventricular administration [38,45,162]. However, its impact on IgG 




FcRn-mediated influx. IgG influx rates are comparable to that of human serum albumin (HSA) [16,113]. It 
is notable that albumin has been reported to bind FcRn [127]. However, cross-species binding between 
mouse FcRn and HSA is weak (86 mM) [5]. Given that picomolar concentrations of radiolabeled HSA are 
used in BBB studies, it is reasonable to conclude that both IgG and HSA primarily use slow extracellular 
pathways to cross the BBB under these conditions [16,113] .  
Supposing that FcRn affects IgG efflux but not influx, a logical conclusion is that FcRn maintains a 
low brain/blood ratio of IgG.  Suprisingly, FcRn knock out mice have the same brain/blood ratio of 
intraveneously administered antibody as wild-type mice [34,61]. One explanation is that FcRn-mediated 
efflux is insignificant under typical IgG peripheral delivery conditions, i.e. therapeutic IgG in the brain is 
zero initially, IgG influx is slow, and IgG recycling is significant. Under these conditions, peripheral 
therapeutic IgG in FcRn knockout mice would be removed via recycling before these levels reach a 
significantly higher level in the brain than in wild-type mice. A second explanation is that multiple IgG 
transporters exist in the BBB that collectively act to maintain an homeostatic brain:plasma equilibrium. 
In this second scenario, FcRn would contribute to the total rate at which this equilibrium is reached but 
not the ultimate equilibrium ratio itself. This second model also necessitates that FcRn would exert a 
small effect on influx to maintain the intrinsic brain:plasma equilibrium.  
      
FcRn-mediated efflux. While even a minor role for FcRn in IgG influx is debatable, the evidence for FcRn 
in IgG efflux is more significant [38,45,162]. Studies have shown that IgG delivered to the brain at high 
concentrations is rapidly depleted to baseline levels via FcRn [38,45,162]. Relative to controls, IgG efflux 
from the brain is significantly lowered in the context of Fc inhibition [162] , FcRn knock-out [45], and 
with low-FcRn-affinity IgG [38]. In addition, the level of FcRn in mouse brain endothelial cells (MBECs) is 
reported to be higher in older mice and Tg2756 AD models [45]. If enhanced IgG efflux is a feature of the 
aging human brain as well, IgG delivery may be particularly compromised in the population with the 
greatest need for AD treatments.   
In a non-pathological context, IgG efflux may play a role in avoiding aberrant inflammation and 
immune responses in the brain [123,130]. In the context of a CNS disorder, this efflux pathway might 
either hinder or help IgG-based immunotherapy depending on the clinical mechanism. If a high IgG 
concentration in the brain was more efficacious, FcRn would hinder treatment by limiting IgG drug 
accumulation in the brain [123]. If repeated IgG transit into and out of the brain is beneficial, as 
hypothesized for a peripheral sink mechanism, FcRn could enhance treatment by accelerating the 
cycling of IgG [63]. Consequently, selective control over this transporter could be highly advantageous in 
IgG clinical applications. 
While conceptually straightforward, modulation of FcRn efflux activity in a patient during IgG 
drug administration will be highly challenging. One approach is to use FcRn inhibitors such as free Fc 
domains, protein A constructs, or small engineered peptides [45,46,75,123,162]. However, any such 
inhibitors would also need to cross the BBB and face the same delivery challenge as the IgG drug they 
are intended to assist.  Additionally, such FcRn inhibitors are also likely to inhibit other FcR species, with 
many potential complications and side-effects [68,123].    
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Another approach is to engineer the IgG therapeutic with reduced FcRn affinity while retaining 
all other functionalities. Such efforts are difficult as any change to the Fc domain will likely alter the IgG 
effector function [1,68]. It is also possible that influx-enhancing peptides, such as K16ApoE, can be 
further engineered to also inhibit FcRn efflux [128].   
 
A role for glycosylation in modulating BBB transport of IgG 
 All IgG’s have a conserved N-linked glycan on N297 of both heavy chains (Figure 2, red and 
yellow glycans) [68]. In addition, Fab domains can exhibit glycans in the variable regions of either heavy 
or light chains (Figure 2, magenta glycan) [147]. For a given IgG population, both Fc and Fab glycans are 
typically highly variable in presentation [9,29,64,81,112,138,139,147]. However, those in the Fab 
domain are more highly processed (longer) that those at the sterically hindered Fc N297 position 
[9,44,64,81,85,138,139,147]. As naturally occurring post-translational modifications, these glycans are 
not technically defined as chemical modifications of their IgG hosts. Nonetheless, varying the 
carbohydrate content and linkage chemistry in IgG glycans has direct consequences on their biological 
activity and therapeutic efficacy [29,68,81,106,147].  
For conserved N297 glycans in the Fc domain, there is a general consensus on two aspects of 
N297 glycosyslation on Fc effector function [68]. First, N297 glycosylation is necessary for FcR binding 
and activation [68]. Second, trimming of galactose termini on the Fc glycan increases the overall immune 
response of the IgG, particularly with respect to complement activation [68]. While a novel anti-
inflammatory role for Fc sialylation has been proposed [7,79,136], this hypothesis has not been 
supported in studies of its molecular mechanism [42,139,159] and functional outcomes in select disease 
models [25,32,64,81,91,108,111,152]. 
In contrast to the relatively well-characterized structure-function relationship of Fc glycans on 
IgG effector function, the biological role and therapeutic consequences of Fab glycosylation is much 
more obtuse [147]. The literature provides examples where Fab glycans are correlated with increased 
antigen affinity [82,88,142,149,154], decreased antigen affinity [36,88,97,131,154], increased 
aggregation [71,80,100], decreased aggregation [40], increased autoimmune reactivity 
[66,122,155,158], as well as immunosuppression in the context of autoimmune disease [155], pregnancy 
[24,29,62,161], B-cell lymphoma [4,98,118,125,131,163], and intravenous immunoglobulin (IVIG) 
treatment [81,96,132,133]. There are also studies that found no correlation between Fab glycosylation 
and IgG antigen binding [37,125] or therapeutic efficacy of IVIG [32,64,91,108]. This diverse range of 
findings demonstrates that the effect of a given Fab glycan on biological properties and therapeutic 
metrics of an IgG drug is difficult to predict. It is also clear that the effects of Fab glycans are highly 
dependent on glycan carbohydrate composition, glycosidic linkage chemistry, glycosylation residue 
position in the IgG chain, local IgG sequence near the glycosylation site, and the biological or therapeutic 
property of interest [147].  Despite this variability, one agreed-upon finding is that sialylation of glycans 
in Fab, but not Fc, extends the IgG serum half-life [3,30,37,103], presumably due to a lack of interaction 
with the asialoprotein glycoreceptor in the liver [10]. 
IgG glycosylation has not been adequately explored with respect to AD immunotherapy.  In an 
effort to develop less inflammatory IgG, one study demonstrated that a deglycosylated mAb engaged A 
in an AD mouse model equally to that of the parent mAb [153]. Interestingly, the humanization process 
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of murine m266 to produce the therapeutic antibody Solanezumab disrupted a N-glycosylation site in 
the heavy chain CDR2 [97]. It is not clear if this change was incidental or intentional. Regardless, the 
therapeutic performance of Solanezumab with human AD patients proved to be much lower than that 
of m266 with AD mouse models [47,54]. It is possible that this difference is the result of an inadequate 
mouse model of AD used to study m266. However, a loss in therapeutic benefit resulting from the 
missing Fab glycan in Solanezumab cannot presently be dismissed.      
Notably absent in the literature is evidence for or against IgG glycan composition as a modulator 
of BBB influx, efflux, and overall penetration. This gap in knowledge exists for all therapeutic antibodies 
and not only for antibodies used for AD treatment. However, a number of lines of evidence suggest that 
glycan modification may enable increased IgG brain penetration and target engagement. A small but 
consistent set of studies has demonstrated that glycans are an important factor regulating penetration 
of blood-borne proteins into the brain. A visual summary of this research is presented in Figure 3. The 
earliest proteins found to exhibit carbohydrate-mediated BBB transcytosis are lectins, plant proteins 
with binding specificity for specific carbohydrate termini of glycans [73,92]. At least three lectins have 
demonstrated increased BBB penetration: wheat germ agglutinin (WGA),  Ricin communis agglutinin I 
(RCAI), and soybean agglutinin (SBA) [31,70,120]. Lectins are a natural candidate for influx via 
adsorptive-mediated transcytosis (AMT) due to their high binding specificity for unique carbohydrate 
units on glycoproteins and glycolipids in the luminal membrane and glycocalyx of BBB ECs [73]. WGA 
binds terminal N-acetylglucosamine (GlcNAc) and sialic acid in a variety of glycosidic linkages and can 
target these groups in the luminal and abluminal membranes of the BBB [70]. RCAI and SBA target 
galactose and N-acetylgalactosamine groups that are also present in the BBB endothelium [120]. AMT 
resulting from specific binding of lectins to endothelial carbohydrates represents a distinct AMT 
pathway from that of polyamines, which bind ECs nonspecifically via electrostatic interactions [114]. 
Aside from the forces stabilizing membrane binding, further mechanistic differences between AMT of 
lectins and polyamines, if any, are unclear.  
Consistent with its ligand  specificity, WGA readily accessed the Golgi transport system of BBB 
ECs and subsequently entered the CNS via a mechanism consistent with AMT [148] WGA binding to ECs 
was inhibited by competitive ligands GlcNAc and sialic acid, demonstrating the importance of 
carbohydrate binding by WGA during its AMT process [120]. Lastly, WGA endocytosis was insensitive to 
a broad panel of pinocytosis, caveolae-mediated and receptor-mediated transcytosis (RMT) inhibitors 
[14]. The high affinity, sialic acid-α2,6-galactose specific lectin Sambucus Nigra Agglutinin (SNA) did not 
exhibit a BBB influx above baseline, suggesting that WGA binds other sialoconjugates, such as α2,3 
linkages, on the cell surface (Figure 4) [15]. Interestingly, excess unlabeled WGA did not inhibit 
radiolabeled WGA influx and instead heightened its influx through the BBB [13]. This positive 
homotropic behavior is observed in select cases of AMT [53,70] but never with RMT [45,87]. 
In contrast with WGA, the elevated BBB influx of RCAI was facilitated by -D-galactosyl-
containing components within caveolae (Figure 3) [70,120]. The location of this neutral sugar in caveolae 
is consistent with the absence of negative charge in this region of the EC membrane [70]. Inhibition by 
free galactose and GalNAc carbohydrates, cell dynamics and endocytosis kinetics, and lack of apparent 
RMT target support an AMT model for RCAI [120]. A lack of EC surface binding by Dolichos bifuros 
agglutinin, which binds only -D-galactosyl species, and Jaccalin, which binds only galactose, indicates 
that RCAI binds -D-GalNAc on ECs [15,120].  The EC-binding lectin SBA has not been studied to the 
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degree WGA and RCAI have [120]. However, its similar ligand-specificity to RCAI and inhibition with a 
galactose/GlcNAc mixture suggests a similar AMT process as RCAI [120]. 
A strong case has also been demonstrated for the importance of 2,3-linked sialic acid in an 
RMT-like influx process the nanobody FC5 through the BBB [2]. FC5 is a single domain VHH derived from 
llamas and its binding was optimized to human BBB endothelial cells using phage display [2,67]. The 
effectiveness of clathrin-pit RMT inhibitors identified the dependence of FC5 influx on a novel BBB 
transporter protein termed Cdc50A, of which few details are known [2,59]. One aspect of Cdc50A that is 
confirmed is that it exhibits surface-accessible 2,3-linked sialic acid groups (illustrated in Figure 4) and 
that binding of FC5 to these groups is necessary for the RMT-like influx of Fc5 [2].                    
A different case of carbohydrate-mediated BBB transcytosis is found with the HIV coat 
glycoprotein gp120 [14]. As with WGA and RCAI, gp120 also appears to exhibit increased brain 
penetration due to AMT. However its initial binding event differs from that of these lectins. The initial 
binding of WGA, RCAI, and SBA to ECs all occur via the binding site on the lectin and a carbohydrate 
ligand on ECs [13,31,120]. By contrast, a glycan carbohydrate on gp120 binds a protein site on the 
surface of ECs to facilitate AMT [14,15,18,53]. Thus, carbohydrates expressed on either the free protein 
or the BBB can mediate BBB influx.       
 Gp120 exhibits a significant BBB influx rate that cannot not be explained with paracellular 
pathways [14]. Although gp120 is not a lectin, both WGA and RCAI lectins stimulated the gp120 influx 
rate and brain penetration [14,15]. This effect was similar to the ability of WGA to self-stimulate its own 
AMT rate [13]. However, addition of unlabeled gp120  did not alter the transcystosis rate of radiolabeled 
gp120 [15]. Together these findings suggest (1) different, but additive, lectin and gp120 AMT 
mechanisms and/or (2) stronger AMT processes induced by the lectins than by gp120 [15]. The 
stimulatory effect of WGA was significantly higher than RCAI suggesting that gp120 bound ECs in regions 
closer to sialoconjugates than caveolae (Figure 3) [15]. The importance of gp120 glycans was 
demonstrated when both the influx of gp120 and its enhancement by WGA was eliminated by gp120 
deglycosylation [15]. A more recent study implicated high mannose glycans on gp120 since HIV BBB 
permeability was reduced by mannose-6-phosphate inhibition, mannan inhibition, and enzymatic 
cleavage of HIV high mannose glycan receptors [53]. This same study also supported an interaction 
between other components of the HIV viral coat and heparin components of the EC glycocalyx, which 
could also be mediated via carbohydrates [53].  
   The implications of the BBB studies with lectins and gp120 for AD immunotherapy with IgG are 
two-fold. First endogenous IgG that either bind or present surface glycans might be capable of access to 
the brain parenchyma at higher levels than those lacking such groups. Presumably, IgG tested in prior 
BBB studies do not exhibit such glycosylation groups [16,113]. Second, engineered glycosylation could 
be used as a minimally perturbative method to increase the BBB penetration of therapeutic antibodies 
for AD. Given that Fc glycans are less sterically accessible than Fab glycans, efforts to add glycans to IgG 
would focus on sites in the Fab domain [64,81,139]. Nonetheless, it may be possible for two fully 
processed Fc glycans to become surface accessible [139,150]. Fc glycosylation may also modulate the Fc 
structure such that BBB penetration is altered via Fc-mediated interactions, such as that with FcRn [45]. 
    The high mannose glycans responsible for increased gp120 BBB influx are rare on typical IgG 
[29,138]. However, evidence suggests that other antibody glycans can also modulate BBB transport. One 
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indirect piece of evidence for this hypothesis is that antibodies of the same class and antigen specificity 
exhibit significantly different rates of BBB influx and efflux [12,19]. A comparison of the BBB kinetics of 
anti-Aβ mouse monoclonal antibodies 4G8 and 6E10 in APP23 mice found both influx and efflux rates to 
be faster for 6E10 than for 4G8 [12]. In addition, the influx and efflux of polyclonal human anti-A 
antibodies was slower than either 4G8 or 6E10 [12]. All these antibody isotypes and subclasses bind  A 
antigens and mouse FcRn with comparable affinity [41,119,123]. Thus, additional factors are necessary 
to explain the differences in BBB transport between these similar IgG species.  
A recent study has demonstrated significant differences in surface presentation of 
glycoconjugates between 6E10, 4G8, and polyclonal human anti-A IgG in intravenous immunoglobulin 
(IVIG) [85]. Mouse IgG1 6E10 was devoid of glycans other than the Fc glycan, and this glycan was 
predominantly (>95%) unsialylated [85]. By contrast, mouse IgG2b 4G8 has a significant fraction of light 
chain Fab domains with a glycan that retains the conventional 2,6 sialic acid terminal groups [85]. 4G8 
Fc sialyation was not detected and removal of the Fc glycan had no effect on surface sialic acid 
presentation and lectin binding [85]. Interestingly, human anti-A IgG from IVIG exhibited a significant 
amount of surface glycans with sialic acid in an non-2,6 linkage with galactose [85]. These differences 
in surface glycan composition may account for the differences in BBB transport rates observed between 
these IgG species in the in vivo mouse study [12]. 
In vitro studies in our labs have confirmed that the addition of surface accessible sialic acid on 
IgG glycans reduces IgG efflux, although no effect on influx was observed (in press). Removal of the Fc 
glycan partially restores the IgG efflux capability, indicating that Fab sialylation plays a role in this 
inhibitory effect but that the Fc glycan is an important factor as well. Interestingly, this efflux was highly 
inhibited even though only 15% of IgG in the sialylated preparation actually presented surface-accessible 
sialic acid (in press). Given that Fc sialylation was negligible in 4G8, we posit that sialylated IgG inhibits 
the efflux of unsialylated IgG (Figure 5). An inhibitory effect between sialylated IgG and other 
unsialylated proteins, including other IgG, remains to be determined. 
Prior studies have implicated FcRn as a significant IgG efflux transporter in the BBB [38,45,130].  
It is therefore possible that FcRn is the efflux transporter inhibited by sialylated 4G8. If so, this inhibition 
would occur under picomolar concentrations of sialylated 4G8. While this hypothesis is tantalizingly 
simple, the actual mode of action may be more complicated. First, sialylated IgG has generally shown to 
have an FcR affinity that is equal to or less favorable than non-sialylated IgG [8]. Second, the removal of 
sialic acid from IVIG and Fc has not been shown to alter its ability to faciliate FcRn blockade in rheumatic 
arthritis animal models [111]. Lastly, sialic acid on glycoproteins is known to bind a range of endogenous 
and exogenous proteins [6,10,30,60] and also impairs IgG binding to natural ligands [36,88]. These 
interactions may inhibit IgG efflux pathways that are independent of FcRn-mediated transcytosis.  
It should be noted that the surface sialic acid in IgG, when present, is predominantly associated 
with glycans in the Fab domains [9,44,64,81,85,138,139,147]. This Fab domain permits a large variation 
in possible presentations of this sialic acid. Thus, binding between Fab sialic acid and other biomolecules 
can vary drastically depending on steric bioavailability, local primary sequence, and non-local tertiary 
IgG structure around the glycosylation site presenting the sialic acid [147]. In an optimal context, the 
affinity of Fab-sialylated IgG could be significantly higher than the Fc domain for FcRn or other BBB 
transporters. While intriguing, the thermodynamics of such factors in surface-sialylated IgG inhibitory 
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binding to RcRn or other transporters is presently unexplored. Further work is needed to adequately 
understand the connection between IgG sialic acid and BBB efflux. 
Therapeutic considerations: Is more always better? 
 Regardless of which strategies gain traction in academic labs and the pharmaceutical industry to 
increase antibody blood-brain barrier penetration, a key factor will be control. Given our current 
inability to deliver antibodies to the brain, a pro and con debate over the merits of delivering high doses 
to the brain might seem counterproductive. However, the root causes of AD remain unclear 
[26,63,90,102]. While the amyloid hypothesis continues to be the leading model of AD pathology, this 
does not preclude other pathological contributions, such as inflammation, as contributors to AD [69].  If 
so, antibody drugs may need to be delivered to the brain within a narrow  concentration range that 
balances the benefits of -amyloid elimination with the potential complications of inflammation [69]. 
Achieving this optimal concentration is best achieved with a BBB delivery method that can be readily 
modulated to achieve optimal therapeutic efficacy. A “toolbox” of different transporter-binding proteins 
or chemical moieties with a range of defined BBB penetration capabilities would be ideal.  
 Most monoclonal therapeutic antibodies for AD are immune system agonists that are intended 
to activate effector function ligands after binding their target [97]. However, an alternate antibody drug 
used to treat AD is IVIG, which is typically used as an immune system antagonist to treat autoimmune 
conditions [43,117,137,146]. Somewhat contradictory to its prescribed applications, the justification for 
IVIG treatment of AD was the presence of anti-Aβ IgG in IVIG and the lack of such antibodies in AD 
patients [49,55,151].  This anti-Aβ IgG component of IVIG may prove beneficial as its specificity for 
oligomeric/fibrillar Aβ, but not monomeric Aβ, is similar to the promising drug aducanumab 
[41,50,119,134]. However, the high doses used in AD clinical trials (> 100 mg/kg) are more consistent 
with immunosuppressive IVIG applications [51,86]. IVIG does provide immune protection for immune-
compromised individuals when applied at low doses [116,145]. But higher doses of IVIG were used in AD 
clinical trials [51,86]. Thus, inflammatory pathways, if present, were suppressed during IVIG treatment 
of AD patients. Given the small possible benefit of IVIG reported for AD patients at the higher doses, one 
cannot rule out a beneficial role for immune system suppression in AD treatment [86].  
 It is notable that sialic acid, posited to increase BBB penetration, has also been proposed as an 
anti-inflammatory moiety in IVIG [7,79,136]. This hypothesis originally focused exclusively on Fc 
sialylation and has since received considerable debate in the literature [25,32,64,81,91,108,111,152]. In 
addition to this putative anti-inflammatory role of Fc sialylation, Fab glycan sialylation has also exhibited 
anti-inflammatory effects in mouse models and in clinical settings [81,106]. At present, the therapeutic 
significance of different glycoforms and linkage sites in therapeutic IgG remains untested with AD. 
Moving forward, a strong argument can be made for investigating anti-Aβ IgG modifications that 
increase BBB penetration and also provide other potential therapeutic benefits, such as a reduction in 








Figure 1. Current methods to increase IgG influx are shown: (1) bispecific antibodies that target 
receptors such as Transferrin Receptor (TfnR) and induce receptor-mediated transcytosis (RMT); (2) 
induction of adsorptive-mediated transcytosis  (AMT) via in-trans delivery of IgG along with small 
peptides that bind both IgG and the a BBB component; (3) induction of AMT via chemically modified IgG 
that bind the BBB endothelium; (4) reduction in size of IgG via unknown mechanism(s); (5) targeted 






Figure 2. Structure of IgG showing the common location and structure of both Fc glycans (red and yellow 
atoms) and one possible location and structure of a single Fab glycan (magenta atoms). The structure 







Figure 3. Summary of carbohydrate-dependent BBB influx pathways found in the literature: (1) The 
engineered VHH nanobody FC5 binds a2,3-linked sialic acid on a largely unknown protein Cdc50A and is 
delivered to the brain through a process resembling RMT; (2) The lectin Ricin Communnis Agglutinin I 
(RCAI) binds N-acetylgalactosamine found in the EC luminal membrane and is transported via AMT(; (3) 
The lectin wheat germ agglutinin (WGA) induces AMT through binding of exposed N-acetylglucosamine 
and/or sialic acid carbohydrates on the BBB endothelium; (4) gp120 presents mannose groups that can 
bind the mannose-6-phosphate receptor (M6PR) and thereby weakly induce AMT. WGA and gp120 have 
a high overlap in their access of endosomal pathways, presumably due to proximity of GlcNAc/sialic acid 





Figure 4. Chemical structure of the (A) 2,3 galactose-sialic acid bond linkage and (B) 2,6 galactose-







Figure 5. Proposed action of sialylated Fab glycan in 4G8 IgG. Sialylation prevents both the sialylated 
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